ADAR1 Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

ADAR1 Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2M	Buy	166,286 +5,948	+4%	+$448K	0.6%	40
2026 Q1	$12M	Buy	160,338 +13,208	+9%	+$1.04M	0.71%	39
2025 Q4	$11.6M	Buy	147,130 +13,312	+10%	+$1M	0.85%	30
2025 Q3	$8.75M	Sell	133,818 -14,643	-10%	-$715K	0.82%	28
2025 Q2	$5.87M	Buy	+148,461	New	+$4.86M	0.9%	30
2024 Q4	–	Sell	-700	Closed	-$28K	–	257
2024 Q3	$28K	Sell	700 -800	-53%	-$37.2K	﹤0.01%	236
2024 Q2	$71.5K	Sell	1,500 -1,400	-48%	-$57.4K	0.01%	182
2024 Q1	$126K	Buy	+2,900	New	+$138K	0.03%	138

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ADAR1 Capital Management's IONS Position: Q2 2026 in Review

ADAR1 Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 3.7% in Q2 2026, buying an estimated $448K and bringing the position to 166,286 shares worth $13.2M. The position accounts for 0.6% of the portfolio, ranked #40.

ADAR1 Capital Management first reported a position in IONS in Q1 2024 and has held it in 8 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

ADAR1 Capital Management held 166,286 shares of Ionis Pharmaceuticals worth $13.2M as of Q2 2026.
ADAR1 Capital Management bought 5,948 Ionis Pharmaceuticals shares in Q2 2026, an estimated $448K.
Ionis Pharmaceuticals made up 0.6% of ADAR1 Capital Management's portfolio in Q2 2026, its #40 holding.
ADAR1 Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.